Marco Colleoni1, Zhuoxin Sun2, Karen N Price2, Per Karlsson2, John F Forbes2, Beat Thürlimann2, Lorenzo Gianni2, Monica Castiglione2, Richard D Gelber2, Alan S Coates2, Aron Goldhirsch2. 1. Marco Colleoni and Aron Goldhirsch, European Institute of Oncology and International Breast Cancer Study Group, Milan; Lorenzo Gianni, Ospedale degli Infermi and Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Rimini, Italy; Zhuoxin Sun, Karen N. Price, and Richard D. Gelber, International Breast Cancer Study Group Statistical Center and Frontier Science and Technology Research Foundation; Zhuoxin Sun and Richard D. Gelber, Harvard T.F. Chan School of Public Health; Richard D. Gelber, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Per Karlsson, Institute of Selected Clinical Sciences, Sahlgrenska Academy, Sahlgrenska University Hospital, Gothenburg, Sweden; John F. Forbes, Australia and New Zealand Breast Cancer Trials Group, University of Newcastle, Newcastle Mater Hospital, Newcastle; Alan S. Coates, International Breast Cancer Study Group and University of Sydney, Sydney, New South Wales, Australia; Beat Thürlimann, Breast Center Kantonsspital, St Gallen, and Swiss Group for Clinical Cancer Research; and Monica Castiglione, International Breast Cancer Study Group, Bern, Switzerland. marco.colleoni@ieo.it. 2. Marco Colleoni and Aron Goldhirsch, European Institute of Oncology and International Breast Cancer Study Group, Milan; Lorenzo Gianni, Ospedale degli Infermi and Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Rimini, Italy; Zhuoxin Sun, Karen N. Price, and Richard D. Gelber, International Breast Cancer Study Group Statistical Center and Frontier Science and Technology Research Foundation; Zhuoxin Sun and Richard D. Gelber, Harvard T.F. Chan School of Public Health; Richard D. Gelber, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Per Karlsson, Institute of Selected Clinical Sciences, Sahlgrenska Academy, Sahlgrenska University Hospital, Gothenburg, Sweden; John F. Forbes, Australia and New Zealand Breast Cancer Trials Group, University of Newcastle, Newcastle Mater Hospital, Newcastle; Alan S. Coates, International Breast Cancer Study Group and University of Sydney, Sydney, New South Wales, Australia; Beat Thürlimann, Breast Center Kantonsspital, St Gallen, and Swiss Group for Clinical Cancer Research; and Monica Castiglione, International Breast Cancer Study Group, Bern, Switzerland.
Abstract
PURPOSE: Predicting the pattern of recurrence can aid in the development of targeted surveillance and treatment strategies. We identified patient populations that remain at risk for an event at a median follow-up of 24 years from the diagnosis of operable breast cancer. PATIENTS AND METHODS: International Breast Cancer Study Group clinical trials I to V randomly assigned 4,105 patients between 1978 and 1985. Annualized hazards were estimated for breast cancer-free interval (primary end point), disease-free survival, and overall survival. RESULTS: For the entire group, the annualized hazard of recurrence was highest during the first 5 years (10.4%), with a peak between years 1 and 2 (15.2%). During the first 5 years, patients with estrogen receptor (ER)--positive disease had a lower annualized hazard compared with those with ER-negative disease (9.9% v 11.5%; P = .01). However, beyond 5 years, patients with ER-positive disease had higher hazards (5 to 10 years: 5.4% v 3.3%; 10 to 15 years: 2.9% v 1.3%; 15 to 20 years: 2.8% v 1.2%; and 20 to 25 years: 1.3% v 1.4%; P < .001). Among patients with ER-positive disease, annualized hazards of recurrence remained elevated and fairly stable beyond 10 years, even for those with no axillary involvement (2.0%, 2.1%, and 1.1% for years 10 to 15, 15 to 20, and 20 to 25, respectively) and for those with one to three positive nodes (3.0%, 3.5%, and 1.5%, respectively). CONCLUSION: Patients with ER-positive breast cancer maintain a significant recurrence rate during extended follow up. Strategies for follow up and treatments to prevent recurrences may be most efficiently applied and studied in patients with ER-positive disease followed for a long period of time.
PURPOSE: Predicting the pattern of recurrence can aid in the development of targeted surveillance and treatment strategies. We identified patient populations that remain at risk for an event at a median follow-up of 24 years from the diagnosis of operable breast cancer. PATIENTS AND METHODS: International Breast Cancer Study Group clinical trials I to V randomly assigned 4,105 patients between 1978 and 1985. Annualized hazards were estimated for breast cancer-free interval (primary end point), disease-free survival, and overall survival. RESULTS: For the entire group, the annualized hazard of recurrence was highest during the first 5 years (10.4%), with a peak between years 1 and 2 (15.2%). During the first 5 years, patients with estrogen receptor (ER)--positive disease had a lower annualized hazard compared with those with ER-negative disease (9.9% v 11.5%; P = .01). However, beyond 5 years, patients with ER-positive disease had higher hazards (5 to 10 years: 5.4% v 3.3%; 10 to 15 years: 2.9% v 1.3%; 15 to 20 years: 2.8% v 1.2%; and 20 to 25 years: 1.3% v 1.4%; P < .001). Among patients with ER-positive disease, annualized hazards of recurrence remained elevated and fairly stable beyond 10 years, even for those with no axillary involvement (2.0%, 2.1%, and 1.1% for years 10 to 15, 15 to 20, and 20 to 25, respectively) and for those with one to three positive nodes (3.0%, 3.5%, and 1.5%, respectively). CONCLUSION:Patients with ER-positive breast cancer maintain a significant recurrence rate during extended follow up. Strategies for follow up and treatments to prevent recurrences may be most efficiently applied and studied in patients with ER-positive disease followed for a long period of time.
Authors: M Gnant; M Filipits; R Greil; H Stoeger; M Rudas; Z Bago-Horvath; B Mlineritsch; W Kwasny; M Knauer; C Singer; R Jakesz; P Dubsky; F Fitzal; R Bartsch; G Steger; M Balic; S Ressler; J W Cowens; J Storhoff; S Ferree; C Schaper; S Liu; C Fesl; T O Nielsen Journal: Ann Oncol Date: 2013-12-16 Impact factor: 32.976
Authors: A Goldhirsch; R D Gelber; K N Price; M Castiglione; A S Coates; C M Rudenstam; J Collins; J Lindtner; A Hacking; G Marini Journal: Lancet Date: 1994-02-12 Impact factor: 79.321
Authors: C Davies; J Godwin; R Gray; M Clarke; D Cutter; S Darby; P McGale; H C Pan; C Taylor; Y C Wang; M Dowsett; J Ingle; R Peto Journal: Lancet Date: 2011-07-28 Impact factor: 79.321
Authors: R Peto; C Davies; J Godwin; R Gray; H C Pan; M Clarke; D Cutter; S Darby; P McGale; C Taylor; Y C Wang; J Bergh; A Di Leo; K Albain; S Swain; M Piccart; K Pritchard Journal: Lancet Date: 2011-12-05 Impact factor: 79.321
Authors: A Goldhirsch; E P Winer; A S Coates; R D Gelber; M Piccart-Gebhart; B Thürlimann; H-J Senn Journal: Ann Oncol Date: 2013-08-04 Impact factor: 32.976
Authors: Gulisa Turashvili; Joanne F Chou; Edi Brogi; Monica Morrow; Maura Dickler; Larry Norton; Clifford Hudis; Hannah Y Wen Journal: Breast Cancer Res Treat Date: 2017-07-12 Impact factor: 4.872
Authors: Shijia Zhang; Sayeed Ikramuddin; Heather C Beckwith; Adam C Sheka; Keith M Wirth; Anne H Blaes Journal: Obes Surg Date: 2020-02 Impact factor: 4.129
Authors: Heather B Neuman; Jessica R Schumacher; Amanda B Francescatti; Taiwo Adesoye; Stephen B Edge; Elizabeth S Burnside; David J Vanness; Menggang Yu; Yajuan Si; Dan McKellar; David P Winchester; Caprice C Greenberg Journal: Ann Surg Oncol Date: 2016-08-04 Impact factor: 5.344
Authors: Jessalyn M Ubellacker; Ninib Baryawno; Nicolas Severe; Molly J DeCristo; Jaclyn Sceneay; John N Hutchinson; Marie-Therese Haider; Catherine S Rhee; Yuanbo Qin; Walter M Gregory; Ana C Garrido-Castro; Ingunn Holen; Janet E Brown; Robert E Coleman; David T Scadden; Sandra S McAllister Journal: Cancer Res Date: 2018-07-31 Impact factor: 12.701
Authors: Ezzeldin M Ibrahim; Marwan R Al-Hajeili; Ali M Bayer; Omalkhair A Abulkhair; Ahmed A Refae Journal: Med Oncol Date: 2017-06-15 Impact factor: 3.064
Authors: Kristen D Brantley; Anders Kjærsgaard; Deirdre Cronin-Fenton; Rami Yacoub; Anja S Nielsen; Kristina L Lauridsen; Stephen Hamilton-Dutoit; Timothy L Lash Journal: Cancer Epidemiol Biomarkers Prev Date: 2018-03-28 Impact factor: 4.254
Authors: Tessa G Steenbruggen; Lars C Steggink; Caroline M Seynaeve; Jacobus J M van der Hoeven; Maartje J Hooning; Agnes Jager; Inge R Konings; Judith R Kroep; Wim M Smit; Vivianne C G Tjan-Heijnen; Elsken van der Wall; Adriaan D Bins; Sabine C Linn; Michael Schaapveld; Judy N Jacobse; Flora E van Leeuwen; Carolien P Schröder; Harm van Tinteren; Elisabeth G E de Vries; Gabe S Sonke; Jourik A Gietema Journal: JAMA Oncol Date: 2020-04-01 Impact factor: 31.777
Authors: Jae Young So; Nicolas Skrypek; Howard H Yang; Anand S Merchant; George W Nelson; Wei-Dong Chen; Hiroki Ishii; Jennifer M Chen; Gangqing Hu; Bhagelu R Achyut; Esther C Yoon; Liying Han; Chuanshu Huang; Margaret C Cam; Keji Zhao; Maxwell P Lee; Li Yang Journal: Cancer Res Date: 2020-04-07 Impact factor: 12.701